相关实验视频

Updated: Aug 25, 2026

Multi-photon Imaging of Tumor Cell Invasion in an Orthotopic Mouse Model of Oral Squamous Cell Carcinoma

Multi-photon Imaging of Tumor Cell Invasion in an Orthotopic Mouse Model of Oral Squamous Cell Carcinoma

Published on: July 25, 2011

FTH1表明预后不佳,并在头部和部状细胞癌中促进转移

Qingyun Liao¹, Jing Yang^2,3, Zhaoyi Lu⁴

¹The First Affiliated Hospital, Department of Otolaryngology, Hengyang Medical School, University of South China, Hengyang, Hunan, China.

|November 29, 2023

概括

费里丁重链 (FTH1) 在头部和部状细胞癌 (HNSCC) 中过度表达,促进瘤进展和转移. FTH1 作为 HNSCC 的潜在预后因素和治疗点.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
癌症研究癌症研究

背景情况:

费里丁重链 (FTH1) 被公认为在癌症中对铁亡调节的作用.
在头角状细胞癌 (HNSCC) 中,FTH1 的非铁死功能在很大程度上仍未被描述.

研究的目的:

研究FTH1在HNSCC中的表达,预后价值和生物功能.
探索FTH1作为HNSCC进展和转移的潜在治疗点.

主要方法:

使用癌症基因组图谱 (TCGA) 数据库对HNSCC中FTH1表达的分析.
免疫组织化学 (IHC) 和西部涂抹以评估HNSCC组织和细胞系中的FTH1蛋白水平.
在HNSCC患者中调查FTH1的预后意义和与临床参数的相关性.

主要成果:

在HNSCC组织中,FTH1显著过度表达.
升高的FTH1表达与HNSCC的不良预后和淋巴结转移相关.
抑制FTH1可以抑制HNSCC的转移和上皮细胞-介质细胞过渡 (EMT).

结论:

在HNSCC的进展和转移中,FTH1起着至关重要的作用.
FTH1显示出作为HNSCC的预后生物标志物的潜力.
FTH1代表了管理HNSCC的有前途的治疗标.

关键词:

生物标志物生物标志物 FTH1 (费里重链) 是一种 HNSCC (头部和部状细胞癌)转移转移转移转移预测预后预测预测

更多相关视频

Four-color Fluorescence Immunohistochemistry of T-cell Subpopulations in Archival Formalin-fixed, Paraffin-embedded Human Oropharyngeal Squamous Cell Carcinoma Samples

Four-color Fluorescence Immunohistochemistry of T-cell Subpopulations in Archival Formalin-fixed, Paraffin-embedded Human Oropharyngeal Squamous Cell Carcinoma Samples

Published on: July 29, 2017

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...